🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Congratulations to this year’s class of Conquer Cancer grant and award recipients! Are you one of them? Tell us in the comments! We can't wait to celebrate with you at #ASCO25. Full list of recipients: brnw.ch/21wSR0A ASCO

#ASCO25 is ALMOST here, and I’m thrilled to kick things off with the OncLive.com National Fellows Forum on Lung Cancer! Looking forward to insightful discussions and connecting with the next generation of thoracic oncologists!

Unfortunately, patritumab deruxtecan (HER3-DXd) will not be an option anytime soon. Merck & Daiichi Sankyo voluntarily withdrew BLA for accelerated approval after phase 3 HERTHENA-Lung02 did not meet OS endpoint vs doublet chemo in #EGFR NSCLC. merck.com/news/patrituma…

2nd year WCMHemOncFellow Dr. Jonathan Lee (@jonathanwlee23) led his OncLive.com fellows’ team, THORacic AvEnGeRs to discuss the effect of PDL1 on outcomes for patients w/ #EGFR lung cancer! #lcsm #ASCO25 WCM Lung Cancer

🚨 New insights in #RETpositive #LungCancer: RET+ NSCLC often express MET & TROP2, moderately HER3 & EGFR, and rarely HER2. ➡️ Multiple membrane targets may co-exist 🧬 Dynamic changes post-treatment — fresh biopsy recommended 💡 Supports ADC & bispecific antibody trials

#ASCO25 - OncLive.com Fellows forum is more than just learning #LungCancer. We make friends, learn from mentors and celebrate birthdays Ben Bleiberg while enjoying great views in Chicago! Benjamin Levy Sarah Waliany, MD, MS Shreyas Kalantri, MD Abner Antonio Murray, MD PhD Sarah Ghosh

Such an incredible group of inspiring fellows and faculty! Thank you OncLive.com and Benjamin Levy for organizing this pre #ASCO2025 fellows forum and to Sandip Patel MD FASCO Eric K. Singhi, MD Kristen A. Marrone, MD Christine Garcia, MD, MPH Narjust Florez, MD, FASCO for taking the time to share your wisdom and guidance!

DB-1310, HER3 ADC. - uORR = 31% in solid tumors - uORR = 44% in EGFR-mutant NSCLC - Unadjudicated ILD/pneumonitis = 5.2% (mostly grade 1, 2). Encouraging activity especially in EGFR-mutant NSCLC #ASCO25

BL-B01D1 (iza-bren), EGFRxHER3 ADC in driver mutation positive NSCLC outside of classical EGFR mutant NSCLC ORR in EGFR exon20ins/non classical EGFR NSCLC = 69.2% Activity also noted across other genomic alterations. #ASCO25

Thank you Conquer Cancer, the ASCO Foundation ASCO for granting me the Young Investigator Award for my work investigating resistance to next-gen #ALK inhibitors for #NSCLC. Enormously grateful for this opportunity & for the incredible mentorship of JessicaJLinMD, our amazing team, & our patients!

Dr. Helena Yu at #ASCO25 with results from REZILIENT1 of zipalertinib in #EGFR exon 20 NSCLC. RR 35% with efficacy after other exon 20 directed therapy like amivantamab. 39% paronychia but none grade 3.

Dr. Li Zhang at #ASCO25 with Opti-TROP-Lung03 with sacituzumab tirumotecan (Sac-TMT) in EGFR NSCLC post TKI and chemo randomized vs docetaxel. Sac-TMT superior: RR 45% vs 16%, PFS 6.9 vs 2.8m HR 0.30, OS immature but HR 0.49 (HR 0.36 adjusted for crossover). Approved in China.

Telisotuzumab adizutecan (ABBV-400, Temab-A) in #EGFR NSCLC at #ASCO25. This is a cMET ADC like Teliso-V but with a topoisomerase 1 inhibitor. Safety notable for myelosuppression, 7% pneumonitis (1 fatal). RR 63%, DOR 9.8m, PFS 10.9m.

Dr. Benjamin Levy presents phase 2 SAVANNAH - randomized subset of savolitinib with osimertinib/placebo in #EGFR NSCLC, MET+ (IHC/FISH) with PD after 1L osimertinib. RR 58% with combo vs 16% with savo alone. In this setting, need to continue EGFR TKI.

More data supports KRASi + IO in 1L NSCLC with mKRAS G12C. Today: olomorasib+pembro with high ORR regardless PDL1. (Adagrasib+pembro ⬆️activity in PDL1>50%) Hwvr, how comut (STK11/KEAP1) impact the efficacy of these combos? Should we add Chemo when exist comut at baseline?#ASCO25

Congratulations to Charlie Rudin & DeLLphi-304 investigators on this practice-changing trial for our patients with small cell lung cancer Memorial Sloan Kettering Cancer Center Tarlatamab in SCLC after Platinum-Based Chemotherapy | New England Journal of Medicine nejm.org/doi/full/10.10…

Striking activity with ABBV-706 SEZ6 ADC in high grade neuroendocrine cancer (NECs) where active therapies are urgently needed. Thank you to the patients and their families. Alissa Cooper, MD #LCSM

💫 Rising star Dr. Catherine Meador with a clear and nuanced discussion of multiple practice changing talks in #SCLC. #ASCO25 MassGeneral News Mass General Cancer Center MGH Thoracic Oncology

Clinical case submissions are now open for the Yin & Yang Lung Cancer Masterclass! July 11-12, 2025 in Milan, Italy <40? Oncologist, surgeon, or rad onc? Submit by June 15! Submit a case on one of the topics: 1️⃣ Multimodal Rx (resectable/LA NSCLC) 2️⃣ Adjuvant EGFR/ALK+ NSCLC 3️⃣

Datopotamab deruxtecan-dlnk receives accelerated FDA approval for treating EGFR-mutated non-small cell lung cancer. 📄 Full details ➡️ bit.ly/44fIz4B #FDAApproval #OncologyNews #NSCLC #AcceleratedApproval